Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The presentations will feature data on approved medicines Polivy (polatuzumab vedotin), Lunsumio (mosunetuzumab), and Columvi (glofitamab), including long-term follow-up and new investigational combination data.
Key Takeaways from Roche’s Presentations
Polivy’s Five-Year Phase III POLARIX Study Data
Five-year data from the phase III POLARIX study (abstract #469) reinforce the potential of Polivy in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) to provide durable and lasting remissions for people with first-line diffuse large B-cell lymphoma (DLBCL). This marks the first time a positive trend in overall survival (OS) has been shown in this patient group, an area that has seen little advancement in nearly two decades.
Lunsumio and Columvi’s Extended Follow-Up Data
Extended follow-up data of up to four years from the pivotal GO29781 study of Lunsumio (abstract #4407) and NP30179 study of Columvi (abstract #865) demonstrate long-lasting remissions and immune system recovery after treatment ends. These studies support the use of fixed-duration bispecific antibodies for third line or later (3L+) follicular lymphoma (FL) and DLBCL, respectively.
Lunsumio Subcutaneous Formulation Data
The first presentation of data for a subcutaneous formulation of Lunsumio monotherapy from the pivotal phase II GO29781 study (abstract #1645) shows high rates of deep and durable responses and low rates and severity of cytokine release syndrome in people with 3L+ FL. Subcutaneously administered Lunsumio could further improve the patient experience by combining shorter administration time with the existing benefits of a fixed-duration and outpatient therapy.
Patient-Reported Outcomes Data from STARGLO Study
New patient-reported outcomes data from the phase III STARGLO study (abstract #5132) indicate comparable health-related quality of life between treatment arms, despite a higher median number of cycles received with the Columvi combination (11 versus 4). Together with the significant improvement in OS observed in the study, these data support the potential benefit for patients with second-line or later DLBCL.
Investigational Study Combinations Data
New and updated data from investigational study combinations of Polivy with bispecific antibodies Lunsumio and Columvi in relapsed or refractory DLBCL, including the phase Ib/II NP39488 (abstract #988) and phase II GO40516 (abstract #989) studies, add to the growing body of evidence demonstrating the potential of novel bispecific antibody/Polivy combinations in earlier treatment lines and support their ongoing phase III development.- Flcube.com
